Unlike full human growth hormone, AOD9604 selectively targets fat tissue without promoting muscle growth
We will ask about this at consultation and coordinate with your GP where appropriate
As of 2026, the FDA has not approved any therapeutic peptides for musculoskeletal or orthopedic applications
Arguments Against the FDAs Decision: Potential Health Benefits: Advocates emphasize the reported benefits observed in animal studies and limited human use, arguing these should be weighed alongside regulatory concerns
Beyond receptor biology, AOD9604 serves as an important analytical reference material in ligand-binding studies, analytical chemistry, peptide stability investigations, pharmacodynamic research, molecular characterization, biomarker evaluation, and assay optimization